Skip NavigationSkip to Content
Return Return to Search Results

Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades

  1. Author:
    Zhang, M. Y.
    Shu, Y.
    Sidorov, I.
    Dimitrov, D. S.

  2. Author Address

    Dimitrov, DS, NCI, Human Immunovirol & Computat Biol Grp, LECB, CCR,NIH, Frederick, MD 21702 USA NCI, Human Immunovirol & Computat Biol Grp, LECB, CCR,NIH, Frederick, MD 21702 USA. NCI, BRP, SAIC Frederick Inc, Frederick, MD 21702 USA.
    1. Year: 2004
  2. Journal: Antiviral Research
    1. 61
    2. 3
    3. Pages: 161-164
  4. Type of Article: Article
  1. Abstract:

    A new human monoclonal antibody (hmAb), designated m 16, was selected by sequential antigen panning (SAP) of a human phage display library against recombinant soluble HIV-1 envelope glycoproteins (Envs) (gp140s) and their complexes with soluble CD4. It bound with high (nM) affinity to gp120 and gp140; the binding was further enhanced by interactions of the Envs with CD4. m16 inhibited cell fusion mediated by the Envs of 9 HIV-1 isolates from clades A, B, E and G with potency on average comparable to that of the broadly neutralizing human monoclonal antibody Fab X5. The identification of a new hmAb with broad neutralizing activity that exhibits differential inhibitory profile suggests a potential for its use as a component of anti-HIV-1 treatments. Published by Elsevier B.V

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel